Paul Choi
Stock Analyst at Goldman Sachs
(3.37)
# 999
Out of 4,761 analysts
97
Total ratings
50%
Success rate
3.94%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $200 → $225 | $152.43 | +47.61% | 4 | Feb 13, 2025 | |
| RGNX REGENXBIO | Downgrades: Neutral | $38 → $14 | $7.27 | +92.57% | 2 | Feb 11, 2025 | |
| DVAX Dynavax Technologies | Downgrades: Sell | $15 → $12 | $13.33 | -9.98% | 3 | Feb 11, 2025 | |
| LNTH Lantheus Holdings | Initiates: Buy | $143 | $78.23 | +82.79% | 1 | Dec 18, 2024 | |
| ESPR Esperion Therapeutics | Reinstates: Neutral | $4 | $1.82 | +119.78% | 8 | Dec 18, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $42 | $50.69 | -17.14% | 7 | Dec 4, 2024 | |
| CYTK Cytokinetics | Downgrades: Neutral | $85 → $60 | $50.26 | +19.38% | 2 | Aug 13, 2024 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $12 | $5.67 | +111.64% | 7 | Aug 9, 2024 | |
| HCM HUTCHMED (China) | Maintains: Neutral | $17 → $19 | $16.11 | +17.94% | 6 | Aug 1, 2024 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 | $1.40 | +471.43% | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $17.77 | +293.92% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $18 | $10.08 | +78.57% | 2 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $20.02 | +59.84% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $28 | $9.57 | +192.58% | 7 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $1.5 → $1 | $0.59 | +69.75% | 7 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $36.85 | +35.69% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.23 | +263.29% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.71 | +183.33% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $39.73 | +51.02% | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.41 | +1,673.05% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $0.29 | +1,300.07% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $36.91 | +360.58% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $2.91 | +175.39% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $13.17 | +150.57% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $58.25 | +92.27% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $120.69 | +11.86% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.93 | +2,045.46% | 2 | Mar 30, 2020 |
Ascendis Pharma
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $152.43
Upside: +47.61%
REGENXBIO
Feb 11, 2025
Downgrades: Neutral
Price Target: $38 → $14
Current: $7.27
Upside: +92.57%
Dynavax Technologies
Feb 11, 2025
Downgrades: Sell
Price Target: $15 → $12
Current: $13.33
Upside: -9.98%
Lantheus Holdings
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $78.23
Upside: +82.79%
Esperion Therapeutics
Dec 18, 2024
Reinstates: Neutral
Price Target: $4
Current: $1.82
Upside: +119.78%
PTC Therapeutics
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $50.69
Upside: -17.14%
Cytokinetics
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $50.26
Upside: +19.38%
Phathom Pharmaceuticals
Aug 9, 2024
Maintains: Neutral
Price Target: $10 → $12
Current: $5.67
Upside: +111.64%
HUTCHMED (China)
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $16.11
Upside: +17.94%
Gossamer Bio
Jun 17, 2024
Maintains: Buy
Price Target: $8
Current: $1.40
Upside: +471.43%
Feb 1, 2024
Initiates: Buy
Price Target: $70
Current: $17.77
Upside: +293.92%
Jul 31, 2023
Maintains: Neutral
Price Target: $11 → $18
Current: $10.08
Upside: +78.57%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $20.02
Upside: +59.84%
Jul 21, 2023
Maintains: Buy
Price Target: $51 → $28
Current: $9.57
Upside: +192.58%
Jul 20, 2023
Maintains: Sell
Price Target: $1.5 → $1
Current: $0.59
Upside: +69.75%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $36.85
Upside: +35.69%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.23
Upside: +263.29%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.71
Upside: +183.33%
Dec 14, 2022
Initiates: Buy
Price Target: $60
Current: $39.73
Upside: +51.02%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.41
Upside: +1,673.05%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $0.29
Upside: +1,300.07%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $36.91
Upside: +360.58%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $2.91
Upside: +175.39%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $13.17
Upside: +150.57%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $58.25
Upside: +92.27%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $120.69
Upside: +11.86%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.93
Upside: +2,045.46%